Focusing on longevity studies, VitaDAO received $4.1 million in funding from a group of investors, including Pfizer Ventures.
Decentralized autonomous organizations (DAO) VitaDAO received investments from pharmaceutical giant Pfizer’s investment arm Pfizer Ventures and from names such as Shine Capital and L1 Digital.
The investment in VitaDAO was also contributed by Balaji Srinivasan, who is involved in longevity studies and is the former CTO of Coinbase.
VitaDAO, an initiative where everyone can participate, brings together people who want to support and fund research on the topic of longevity. To date, VitaDAO has provided more than $3.5 million in funding to more than 15 projects working to extend human life.
After this investment by VitaDAO, the VITA token also started to appreciate rapidly. VITA, which was traded at $ 1.12 the other day, within 24 hours according to CoinGecko data. $1.54, up more than 37% level rose.
A relatively small token in terms of market cap, VITA has a total market cap of $36 million.